Evidence map›Paper›PMID 26409566›Full record

ArticleNeuro-oncology2016

Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.

Kai Wang, Yinyan Wang, Xing Fan, Jiangfei Wang, Guilin Li, Jieling Ma, Jun Ma, Tao Jiang, Jianping Dai

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Multimodal MRI andDiagnostics (Basel, Switzerland) · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Kai WangDepartment of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (K.W., J.M., J.M., J.D.); Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (Y.W., X.F., J.W., T.J.); Department of Pathology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (G.L.); Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (Y.W., X.F., T.J., J.D.); Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China (T.J.).
Yinyan WangDepartment of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (K.W., J.M., J.M., J.D.); Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (Y.W., X.F., J.W., T.J.); Department of Pathology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (G.L.); Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (Y.W., X.F., T.J., J.D.); Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China (T.J.).
Xing FanDepartment of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (K.W., J.M., J.M., J.D.); Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (Y.W., X.F., J.W., T.J.); Department of Pathology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (G.L.); Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (Y.W., X.F., T.J., J.D.); Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China (T.J.).
Jiangfei WangDepartment of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (K.W., J.M., J.M., J.D.); Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (Y.W., X.F., J.W., T.J.); Department of Pathology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (G.L.); Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (Y.W., X.F., T.J., J.D.); Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China (T.J.).
Guilin LiDepartment of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (K.W., J.M., J.M., J.D.); Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (Y.W., X.F., J.W., T.J.); Department of Pathology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (G.L.); Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (Y.W., X.F., T.J., J.D.); Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China (T.J.).
Jieling MaDepartment of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (K.W., J.M., J.M., J.D.); Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (Y.W., X.F., J.W., T.J.); Department of Pathology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (G.L.); Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (Y.W., X.F., T.J., J.D.); Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China (T.J.).
Jun MaDepartment of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (K.W., J.M., J.M., J.D.); Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (Y.W., X.F., J.W., T.J.); Department of Pathology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (G.L.); Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (Y.W., X.F., T.J., J.D.); Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China (T.J.).
Tao JiangDepartment of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (K.W., J.M., J.M., J.D.); Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (Y.W., X.F., J.W., T.J.); Department of Pathology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (G.L.); Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (Y.W., X.F., T.J., J.D.); Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China (T.J.).
Jianping DaiDepartment of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (K.W., J.M., J.M., J.D.); Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (Y.W., X.F., J.W., T.J.); Department of Pathology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China (G.L.); Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (Y.W., X.F., T.J., J.D.); Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China (T.J.).
Beijing Tian Tan Hospital · CNBeijing Institute of Neurosurgery · CNCapital Medical University · CNChinese Institute for Brain Research · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiological characteristics may reflect the biological features of brain tumors and may be associated with genetic alterations that occur in tumorigenesis. This study aimed to investigate the relationship between radiological features and IDH1 status as well as their predictive value for survival of glioblastoma patients.

methodsThe clinical information and MR images of 280 patients with histologically confirmed glioblastoma were retrospectively reviewed. The radiological characteristics of tumors were examined on MR images, and the IDH1 status was determined using DNA sequencing for all cases. The Kaplan-Meier method and Cox regression model were used to identify prognostic factors for progression-free and overall survival.

resultsThe IDH1 mutation was associated with longer progression-free survival (P = .022; hazard ratio, 0.602) and overall survival (P = .018; hazard ratio, 0.554). In patients with the IDH1 mutation, tumor contrast enhancement and peritumoral edema indicated worse progression-free survival (P = .015 and P = .024, respectively) and worse overall survival (P = .024 and P = .032, respectively). For tumors with contrast enhancement, multifocal contrast enhancement of the tumor lesion was associated with poor progression-free survival (P = .002) and poor overall survival (P = .010) in patients with wild-type IDH1 tumors.

conclusionsCombining the radiological features and IDH1 status of a tumor allows more accurate prediction of survival outcomes in glioblastoma patients. The complementary roles of genetic changes and radiological features of tumors should be considered in future studies.

Indexed as

Biomarkers, TumorBrain NeoplasmsFemaleFollow-Up StudiesGlioblastomaHumansIsocitrate DehydrogenaseMagnetic Resonance ImagingMaleMiddle AgedMutationNeoplasm StagingPrognosisRetrospective StudiesSurvival RateBiomarkers, TumorIDH1 protein, humanIsocitrate DehydrogenaseglioblastomaIDH1radiologysurvival outcome

Identifiers

PMID26409566
PMCPMC4799681
OpenAlexW2289535596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.